Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis

Int J Dermatol. 1993 Jan;32(1):68-70. doi: 10.1111/j.1365-4362.1993.tb00975.x.

Abstract

Background: The aim of this study was to evaluate the effect of topical paromomycin treatment on the development of immunity during cutaneous leishmaniasis.

Methods: Three parameters of immunity were measured in the course of the disease: leishmanicidal effector activity, lymphocyte proliferation (cell-mediated immunity), and antibody levels (humoral immunity). Peripheral blood specimens of 55 treated and 36 untreated patients were tested.

Results: The main results of this study showed that there was a significant delay in the development of leishmanicidal effector activity and to a lesser extent also a delay in the development of antigen-specific proliferative response in the treated compared with the untreated group. No difference was observed between the groups regarding the values achieved in the various tests.

Conclusions: These results suggest that topical paromomycin treatment delays the development of cell-mediated immunity but does not affect the levels of immunity that are eventually achieved.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Cutaneous
  • Antibodies, Protozoan / blood
  • Humans
  • Immunity, Cellular / drug effects
  • Leishmaniasis, Cutaneous / blood
  • Leishmaniasis, Cutaneous / drug therapy*
  • Leishmaniasis, Cutaneous / immunology*
  • Paromomycin / pharmacology
  • Paromomycin / therapeutic use*

Substances

  • Antibodies, Protozoan
  • Paromomycin